Caprock Group, Inc. Xenon Pharmaceuticals Inc. Transaction History
Caprock Group, Inc.
- $4.51 Billion
- Q4 2025
A detailed history of Caprock Group, Inc. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Caprock Group, Inc. holds 5,069 shares of XENE stock, worth $206,612. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,069Holding current value
$206,612% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding XENE
# of Institutions
243Shares Held
74.3MCall Options Held
235KPut Options Held
271K-
Avoro Capital Advisors LLC New York, NY5.4MShares$220 Million2.96% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.17MShares$170 Million1.42% of portfolio
-
Janus Henderson Group PLC London, X03.94MShares$161 Million0.08% of portfolio
-
Wellington Management Group LLP Boston, MA3.61MShares$147 Million0.03% of portfolio
-
Braidwell LP Stamford, CT3.61MShares$147 Million8.35% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.54B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...